Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Advanced liver cancer is difficult to treat, but with the addition of sorafenib (Nexavar) and then regorafenib, both doctors and patients are becoming more optimistic now that there are promising first- and second-line options. 

Bruix predicts that there will soon be an update to clinical practice guidelines to include regorafenib. Also, he is optimistic that after previous trial failures, the success of regorafenib will lead to even more research and developments for liver cancer.

View more from the 2016 World Congress on GI Cancer

Videos

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC). 

Dr. Jordi Bruix, MD

Articles

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment